Five years ago, this patient with pancreatic cancer underwent cellular immunotherapy. How is his condition now?

时间：2026-04-27　人气：

Cancer is not scary, it can be prevented and treated. The key is to have the correct concept and scientific methods!

-<」 Tsinghua University Zhang Minghui< H4>

Case analysis: If you can't understand the subsequent professional description

, if you can't understand the subsequent professional description

, you can read the text in two minutes, and then you can see that Mr. Wang suffers from pancreatic cancer. He has been using it since the end of surgery and adjuvant radiotherapy NKT cell therapy was maintained, and soon entered the sixth year, pancreatic cancer could be controlled for 66 months without recurrence and metastasis, which was a very encouraging and exciting medical miracle. (Mr. Wang's previous cases can be found at the end of the article).

In fact, the condition of many cancer patients changes every year, so continuous tracking and display can dynamically prove the efficacy.

Today, I will report on his situation in 2020.

In February 2015, Mr. Wang underwent pancreaticococcygeal and splenectomy. Postoperative pathology revealed moderately differentiated ductal adenocarcinoma of the pancreas, with nerve invasion and necrosis, involving the peripancreatic fat, but not the spleen. No lymph node metastasis was found. Postoperative staging was T2N0M0 stage Ib. Postoperative adjuvant radiotherapy was administered 35 times. Although Mr. Wang's pathological stage was relatively early, he had nerve invasion, necrosis, and involvement of the peripancreatic fat. Moreover, this disease is highly malignant. Even after adjuvant radiotherapy, it cannot be taken lightly, as chemotherapy and radiotherapy generally only provide short-term efficacy and cannot maintain long-term effects.

Pancreatic cancer is a highly malignant tumor with an insidious onset and difficult early diagnosis. 5% of patients lose the opportunity for surgery at initial diagnosis, earning it the title of "king of cancers." The median survival time for pancreatic cancer is only 6 to 9 months. Surgery is the main treatment method, but the postoperative recurrence and metastasis rates are also extremely high, and the disease is not very sensitive to chemotherapy.

At this time, a treatment method is needed that employs low-frequency intervention to stabilize and maintain long-term efficacy, and delay the time of recurrence and metastasis. After comparing various treatment methods, Mr. Wang decided to start NKT cell immunotherapy in April 2015. To date (as of October 2020), he has undergone 40 treatments over 66 months, with stable disease during follow-up and no clear signs of tumor recurrence on imaging. The tumor marker CA19-9, an important indicator for follow-up of pancreatic cancer treatment, decreased to normal range after surgery, and remained within the normal range during several follow-up examinations. Currently, the patient reports that his hair has turned from white to black, his hair quality has improved, his skin has become rosy and fair, his mental state is good, his appetite and sleep are excellent, and his quality of life is good.

Treatment Overview

The patient's main complaint was weight loss accompanied by poor appetite, abdominal distension, and abnormal bowel movements, with no apparent cause. In February 2015, the patient visited the Cancer Hospital of the Chinese Academy of Medical Sciences. CT and MR imaging revealed a mass in the pancreatic body, and a pancreatectomy of the pancreatic body and tail with splenectomy was performed on February 28th. Postoperative pathology showed moderately differentiated ductal adenocarcinoma of the pancreas, with nerve invasion and necrosis, involving the peripancreatic fat, but not the spleen. No lymph node metastasis was found. BRAF-V600E(-), Ki67 (25%), postoperative staging was T2N0M0 stage Ib. The patient underwent adjuvant radiotherapy for 35 sessions after surgery. NKT therapy was initiated in April 2015 with a 4+4 regimen, and later the regimen was changed to one course every three months due to stable disease. As of August 2020, the patient has undergone a total of 40 courses of treatment, with stable disease and no signs of recurrence or metastasis during follow-up. Currently, the patient is in good mental state, with good appetite and sleep, and a good quality of life.

Imaging data

Abdominal CT: From April 2015 to October 2019, multiple cysts were observed in the liver, with a possible hemangioma in the right posterior lobe. The gallbladder, spleen, and pancreatic body and tail were not shown. Postoperative changes were considered, and no clear signs of recurrence or metastasis were observed around the lesions (PET-CT image from March 2016).

Abdominal CT: Re-examination in September 2020 showed the lowest level, with no lesions observed.

Tumor markers< H185>

Tumor markers: CA19-9 decreased to the normal range after surgery in February 2015, and was regularly monitored to be within the normal range. It increased in May 2019, returned to the normal range after re examination in October 2019, and slightly increased after re examination in September 2020. Pay close attention to monitoring.

NKT Classic Case Review

Click on the image

to view

"Exciting! Pancreatic cancer has not recurred or metastasized in the past five years. How can we do that? 》

[pancreatic cancer, NKT Treatment Case Display] Tsinghua NKT · Lehe Family and Friends · 2015-03

Science popularization is a charity
<<<Long press to recognize QR code

Follow Tsinghua Cell Therapy

If you like it, just click"Watching"H274>Bar

上一篇：没有了

下一篇：肝癌患者8个月内复发3次，经过免疫治疗后，5年未见复发

About Lehe

Corporate Culture Founder's Introduction Lehe News Story of Lehe Science Popularization Academic Literature

New Medical Services

Second Consultation Rehabilitation and Wellness Elite Care

Oncology Clinical Research

Lung Cancer Stomach Cancer Hepatobiliary and Pancreatic Cancers Intestine Cancer Breast Cancer B-cell lymphoma Cervical Cancer Other Solid Tumors

Chronic Disease Research

Hypertension Diabetes Obesity Immune Diseases Degenerative Diseases Chronic Inflammation Others

Contact Us

Address: Room 1101 (Unit 101), 11th Floor, Building 1, No. 7 Courtyard, Kexueyuan Road, Life Science Park, Changping District, Beijing
Phone：010-8265 9866
Email：lehemedneo@hotmail.com

Copyright©2022 Beijing Lehe New Medical Clinic Co., Ltd. All Rights Reserved ICP: 京ICP备2025148232号京公网安备11011402054997号 Privacy Policy